Tag: value

Dublin, June 20, 2025 (GLOBE NEWSWIRE) -- The "Cancer Monoclonal Antibody Collaboration and Licensing Deals 2016-2025" has been added to ResearchAndMarkets.com's offering.

This report contains a comprehensive listing of 632 cancer monoclonal antibody deals announced since 2016 including financial terms where available, as well as links to online deal records of actual cancer monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Fully revised and updated, the report provides details of cancer monoclonal antibody deals from 2016 to 2025. Cancer Monoclonal Antibody Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the cancer monoclonal antibody deals entered into by the world's leading biopharma companies.

The report provides a detailed understanding and analysis of how and why companies enter cancer monoclonal antibody deals. These deals tend to be multicomponent, starting with collaborative R&D and commercialization of outcomes. The report includes collaboration, development, research, and licensing deals.

The initial chapters of this report provide an orientation of cancer monoclonal antibody dealmaking. It starts with an introduction to the report, followed by an overview of the trends in cancer monoclonal antibody dealmaking since 2016. The chapters progress by covering the leading deals by headline value, listing the top 25 most active companies in this domain, and reviewing detailed and comprehensive accounts of deals signed and announced since January 2016, categorized by technology type in focus.

The report also includes numerous tables and figures that illustrate the trends and activities in cancer monoclonal antibody deal making since 2016. In addition, a comprehensive deal directory is provided organized by company A-Z, deal type, and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Cancer Monoclonal Antibody Collaboration and Licensing Deals provides the reader with the following key benefits:

Denver, Colorado, USA, June 20, 2025 (GLOBE NEWSWIRE) -- As the conflict between Israel and Iran continues to escalate, global financial markets are once again hit by risk aversion. Both stocks and crypto assets are under pressure, and according to Cointelegraph, Bitcoin once fell to the $103,000 range. However, against the backdrop of accumulating geopolitical risks, Bitcoin's decentralization and value storage attributes are being refocused and allocated by more investors.

REMARKABLY PRESERVED 1962 SHELBY 260 COBRA, ONE OF THE ORIGINAL PROTOTYPE EXAMPLES, OFFERED FROM 36 YEARS OF CHERISHED LONGTERM OWNERSHIP | COBRA JOINED BY MODERN AMERICAN AUTOMOTIVE LEGENDS: HENNESSEY VENOM GT AND THE AMERICAN PERFORMANCE COLLECTION OF DODGE AND CHEVROLET ICONS

AUGA group, AB entity under restructuring (code 126264360, registered office at Konstitucijos pr. 21C, Vilnius, hereinafter referred to as the “Company”), by the initiative and decision of the Board, is convening an Extraordinary General meeting of shareholders on July 14, 2025, at 10:00 a.m., where the Company’s shareholders will vote on the approval of the Company’s draft restructuring plan, hereinafter referred to as the “Meeting”.

Poinciana, Fl, June 20, 2025 (GLOBE NEWSWIRE) -- SanMelix, the company behind BeeCure Radiation Burn Relief Cream, is excited to announce the addition of Mr. Ajay Dhaul to our Board of Directors and Executive Leadership team in the role of Chief Strategy & Growth Officer, effective June 9, 2025.

BEVERLY, Mass., June 20, 2025 (GLOBE NEWSWIRE) -- ATN International, Inc. (Nasdaq: ATNI) announced that its Board of Directors has approved a quarterly dividend increase of 15% to $0.275 per share. The quarterly dividend will be payable on July 7, 2025, on all common shares outstanding to stockholders of record as of June 30, 2025.